缬沙坦联合双氢克尿噻治疗高血压

Management of Hypertension with Valsartan and Hydrochlorothiazide Combination Therapy

大多数高血压患者需要一个以上药物以达到血压充分的控制,纈沙坦(val)联用双氢克尿噻(HCTZ)比单药val或HCTZ都使血压更显著的下降,并且耐受良好,比单用HCTZ更少低钾血症;val160mg/HCTZ12.5mg比络活喜10mg对高危高血压患者的血压有更持久平稳的控制,而无反射性交感激活,其不良事件和停药率均比络活喜显著低;在高危高血压患者val减少发生糖尿病的危险。较大的起始剂量可使患者起始获得更多的血压下降并更快的达到血压目标。研究提示其在防护心血管、肾血管及脑血管事件上,具有超过降压效应以外的有益作用。

Most hypertensive patients require more than one drug for adequate blood pressure control, Valsartan （ val）/HCTZ combination therapy is associated with significantly greater blood pressure reductions compared with either monotherapy. It is well tolerated with less hypokalemia than HCTZ alone, Val 160 mg/HCTZ 12, 5 mg provides more sustained and homogeneous control of blood pressure than does amlodipine 10 mg in high-risk hypertensive patients ,without producing reflex sympathetic activation, It has markedly lower rate of adverse events and discontinuations than amlodipine. Val reduces the risk of developing diabetes mellitus in high-risk hypertensive patients. Higher starting doses may enable patients to achieve greater initial blood pressure reductions and reach blood pressure goal more rapidly. Studies suggests a beneficial role beyond the antihypertensive effect of this therapy in providing protection against cardiovascular, renovaseular, and eerebrovaseular events.